Role of endothelial cells in pulmonary fibrosis via SREBP2 activation

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. Despite endothelial cells (ECs) comprising 30% of the lung cellular composition, the role of EC dysfunction in pulmonary fibrosis (PF) remains unclear. We hypothesize that sterol regulatory element-binding protein 2 (SREBP2) plays a critical role in the pathogenesis of PF via EC phenotypic modifications. Transcriptome data demonstrate that SREBP2 overexpression in ECs led to the induction of the TGF, Wnt, and cytoskeleton remodeling gene ontology pathways and the increased expression of mesenchymal genes, such as snail family transcriptional repressor 1 (snai1), α-smooth muscle actin, vimentin, and neural cadherin. Furthermore, SREBP2 directly bound to the promoter regions and transactivated these mesenchymal genes. This transcriptomic change was associated with an epigenetic and phenotypic switch in ECs, leading to increased proliferation, stress fiber formation, and ECM deposition. Mice with endothelial-specific transgenic overexpression of SREBP2 (EC-SREBP2[N]-Tg mice) that were administered bleomycin to induce PF demonstrated exacerbated vascular remodeling and increased mesenchymal transition in the lung. SREBP2 was also found to be markedly increased in lung specimens from patients with IPF. These results suggest that SREBP2, induced by lung injury, can exacerbate PF in rodent models and in human patients with IPF.

[1]  A. Shilatifard,et al.  Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis , 2019, American journal of respiratory and critical care medicine.

[2]  Kathy O. Lui,et al.  Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases , 2018, Nature Reviews Cardiology.

[3]  F. Lyko.  The DNA methyltransferase family: a versatile toolkit for epigenetic regulation , 2017, Nature Reviews Genetics.

[4]  P. ten Dijke,et al.  TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases , 2017, International journal of molecular sciences.

[5]  E. Dejana,et al.  The molecular basis of endothelial cell plasticity , 2017, Nature Communications.

[6]  J. Rabinowitz,et al.  Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP. , 2016, Cell metabolism.

[7]  J. Burns,et al.  The Spectrum of Cardiovascular Lesions Requiring Intervention in Adults After Kawasaki Disease. , 2016, JACC. Cardiovascular interventions.

[8]  F. Mendoza,et al.  Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases , 2016, Journal of clinical medicine.

[9]  M. Kreuter,et al.  Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives , 2015, BioMed research international.

[10]  S. Weiss,et al.  Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease , 2015, Nature Medicine.

[11]  R. Kalluri,et al.  Epithelial to Mesenchymal Transition induces cell cycle arrest and parenchymal damage in renal fibrosis , 2015, Nature Medicine.

[12]  B. Morrissey,et al.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. , 2015, Journal of thoracic disease.

[13]  B. Chowdhury,et al.  Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. , 2015, The New England journal of medicine.

[14]  Hsien-Da Huang,et al.  Oxidative Stress Activates Endothelial Innate Immunity via Sterol Regulatory Element Binding Protein 2 (SREBP2) Transactivation of MicroRNA-92a , 2015, Circulation.

[15]  S. Harari,et al.  Cellular interactions in the pathogenesis of interstitial lung diseases , 2015, European Respiratory Review.

[16]  Howard Y. Chang,et al.  ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide , 2015, Current protocols in molecular biology.

[17]  M. Maleszewska.  From microenvironment to epigenetics in endothelial cells , 2015 .

[18]  B. Purnell.  Epigenetics Direct Transdifferentiation , 2014, Science Signaling.

[19]  D. Brenner,et al.  Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. , 2014, The Journal of clinical investigation.

[20]  F. Camargo,et al.  Yap1 Is Required for Endothelial to Mesenchymal Transition of the Atrioventricular Cushion* , 2014, The Journal of Biological Chemistry.

[21]  H. Collard,et al.  Pathogenesis of idiopathic pulmonary fibrosis. , 2014, Annual review of pathology.

[22]  H. Collard,et al.  Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. , 2014, American journal of respiratory and critical care medicine.

[23]  T. Oury,et al.  Animal models of fibrotic lung disease. , 2013, American journal of respiratory cell and molecular biology.

[24]  K. Gowdy,et al.  Emerging roles for cholesterol and lipoproteins in lung disease. , 2013, Pulmonary pharmacology & therapeutics.

[25]  Traci L. Marin,et al.  Sterol Regulatory Element Binding Protein 2 Activation of NLRP3 Inflammasome in Endothelium Mediates Hemodynamic-Induced Atherosclerosis Susceptibility , 2013, Circulation.

[26]  Carmen Z. Cantemir-Stone,et al.  Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. , 2013, American journal of respiratory and critical care medicine.

[27]  T. Albertson,et al.  A review of current and novel therapies for idiopathic pulmonary fibrosis. , 2013, Journal of thoracic disease.

[28]  Gretchen J. Mahler,et al.  Inflammatory Cytokines Promote Mesenchymal Transformation in Embryonic and Adult Valve Endothelial Cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[30]  Oliver Eickelberg,et al.  The impact of TGF-β on lung fibrosis: from targeting to biomarkers. , 2012, Proceedings of the American Thoracic Society.

[31]  Xiangyu Zhang,et al.  Altered DNA methylation profile in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[32]  C. Barkauskas,et al.  Pulmonary fibrosis: patterns and perpetrators. , 2012, The Journal of clinical investigation.

[33]  S. Jimenez,et al.  Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases , 2012, Fibrogenesis & tissue repair.

[34]  V. Fuster,et al.  Epithelial-to-Mesenchymal and Endothelial-to-Mesenchymal Transition: From Cardiovascular Development to Disease , 2012, Circulation.

[35]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[36]  Raúl San José Estépar,et al.  Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. , 2012, American journal of respiratory and critical care medicine.

[37]  N. Dulin,et al.  Actin cytoskeleton in myofibroblast differentiation: ultrastructure defining form and driving function. , 2011, Translational research : the journal of laboratory and clinical medicine.

[38]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[39]  H. Chapman,et al.  Epithelial-mesenchymal interactions in pulmonary fibrosis. , 2011, Annual review of physiology.

[40]  Cole Trapnell,et al.  Improving RNA-Seq expression estimates by correcting for fragment bias , 2011, Genome Biology.

[41]  K. Pritchard,et al.  Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung , 2010, Journal of Lipid Research.

[42]  T. Kawabe,et al.  Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. , 2010, American journal of respiratory cell and molecular biology.

[43]  Daniel S. Ory,et al.  miR-33 links SREBP-2 induction to repression of sterol transporters , 2010, Proceedings of the National Academy of Sciences.

[44]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[45]  K. Moore,et al.  NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease , 2010, Nature.

[46]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[47]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[48]  H. Young,et al.  Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. , 2009, American journal of respiratory cell and molecular biology.

[49]  Nathaniel D. Heintzman,et al.  Histone modifications at human enhancers reflect global cell-type-specific gene expression , 2009, Nature.

[50]  A. Tall,et al.  Increased Inflammatory Gene Expression in ABC Transporter–Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions , 2008, Circulation.

[51]  P. Thompson,et al.  Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. , 2008, Chest.

[52]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[53]  C. Marsh,et al.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. , 2008, Antioxidants & redox signaling.

[54]  Andrew J. Brown,et al.  SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. , 2006, The Biochemical journal.

[55]  G. Laurent,et al.  Pulmonary fibrosis: searching for model answers. , 2005, American journal of respiratory cell and molecular biology.

[56]  E. Wingender,et al.  MATCH: A tool for searching transcription factor binding sites in DNA sequences. , 2003, Nucleic acids research.

[57]  D. Dearnaley,et al.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[59]  Alexander E. Kel,et al.  MATCHTM: a tool for searching transcription factor binding sites in DNA sequences , 2003, Nucleic Acids Res..

[60]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[61]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[62]  D. White,et al.  Bleomycin-induced pulmonary toxicity. , 1990, Clinics in chest medicine.

[63]  N. Simionescu,et al.  Development of intracellular lipid deposits in the lipid-laden cells of atherosclerotic lesions. A cytochemical and ultrastructural study. , 1987, Atherosclerosis.

[64]  J. Lazo,et al.  Bleomycin hydrolase activity in pulmonary cells. , 1984, The Journal of pharmacology and experimental therapeutics.

[65]  J. Crapo,et al.  Cell number and cell characteristics of the normal human lung. , 1982, The American review of respiratory disease.